Today's letter from the Editor
Today's Matrices
iJobs Job Widget
iJobs General

Ashdown Group: Helpdesk Analyst - Devon - £20,000

£18000 - £20000 per annum: Ashdown Group: Helpdesk Analyst - Devon - £20,000 ...

Ashdown Group: Data Scientist - London - £50,000 + bonus

£35000 - £50000 per annum + generous bonus: Ashdown Group: Business Analytics ...

Ashdown Group: IT Project Coordinator (Software Development) - Kingston

£45000 - £50000 per annum: Ashdown Group: IT Project Coordinator (Software Dev...

Ashdown Group: Editor-in-chief - Financial Services - City, London

£60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...

i Editor's Letter: Big pharma should charge fairer prices

 

How can a cancer drugs fund, set up to save people’s lives, be divisive? Because, critics say, it prioritises a select group of seriously ill patients over others, whose deaths are considered less politically problematic.

The cancer fund, which David Cameron plans to extend to 2016 with another £400m of public money, allows doctors to prescribe drugs even where they have been judged “poor value for money” by the UK’s national (English and Welsh) medicines advisory body. Value for money can mean, in its starkest terms: will this expensive drug save someone from cancer ... or prolong their life by a few weeks or months? When the Coalition created the fund, it meant fewer doctors had to tell patients the appalling news that, “Yes, there is a way we could let you live longer, but we won’t, because it’s just too pricey, sorry.”

Happy news? Undoubtedly for the 34,000 patients who have benefited so far, and their families and friends. But some doctors say the cancer drugs fund is “the triumph of political expediency over rationality… the product of opportunism and intellectual incoherence”. Strong words.

What’s the real cancer killer here? Eye-watering profiteering from pharmaceutical firms, I say. Pharma research costs are high, competition is fierce, firms have a duty to shareholders to deliver profits, and their products are allowing more and more people with diseases once fatal to look forward to near-normal life expectancy. But treatments cost tens of thousands of pounds per patient per year – and there are plenty of examples of drugs prices going up as the production costs come down, once firms see they’ve captured the market. Time for a £500bn global industry to charge fairer prices.

i@independent.co.uk

Twitter.com: @olyduff

Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Career Services

Day In a Page

General Election 2015: Ed Miliband's unlikely journey from hapless geek to heart-throb

Miliband's unlikely journey from hapless geek to heart-throb

He was meant to be Labour's biggest handicap - but has become almost an asset
General Election 2015: A guide to the smaller parties, from the the National Health Action Party to the Church of the Militant Elvis Party

On the margins

From Militant Elvis to Women's Equality: a guide to the underdogs standing in the election
Amr Darrag: Ex-Muslim Brotherhood minister in exile still believes Egypt's military regime can be replaced with 'moderate' Islamic rule

'This is the battle of young Egypt for the future of our country'

Ex-Muslim Brotherhood minister Amr Darrag still believes the opposition can rid Egypt of its military regime and replace it with 'moderate' Islamic rule, he tells Robert Fisk
Why patients must rely less on doctors: Improving our own health is the 'blockbuster drug of the century'

Why patients must rely less on doctors

Improving our own health is the 'blockbuster drug of the century'
Sarah Lucas is the perfect artist to represent Britain at the Venice Biennale

Flesh in Venice

Sarah Lucas has filled the British pavilion at the Venice Biennale with slinky cats and casts of her female friends' private parts. It makes you proud to be a woman, says Karen Wright
11 best anti-ageing day creams

11 best anti-ageing day creams

Slow down the ageing process with one of these high-performance, hardworking anti-agers
Juventus 2 Real Madrid 1: Five things we learnt, including Iker Casillas is past it and Carlos Tevez remains effective

Juventus vs Real Madrid

Five things we learnt from the Italian's Champions League first leg win over the Spanish giants
Ashes 2015: Test series looks a lost cause for England... whoever takes over as ECB director of cricket

Ashes series looks a lost cause for England...

Whoever takes over as ECB director of cricket, says Stephen Brenkley
Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

Fishing is on Nigel Farage's mind

Ukip leader casts a line to the disaffected
Who is bombing whom in the Middle East? It's amazing they don't all hit each other

Who is bombing whom in the Middle East?

Robert Fisk untangles the countries and factions
China's influence on fashion: At the top of the game both creatively and commercially

China's influence on fashion

At the top of the game both creatively and commercially
Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

The man known as GOD has a reputation for getting the job done

Lord O'Donnell's three principles of rule
Rainbow shades: It's all bright on the night

Rainbow shades

It's all bright on the night
'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power